Gadicke Ansbert's Form 4 filing

iTeos Therapeutics, Inc. (ITOS) · filed Oct 5, 2021

Accession no.: 0001209191-21-059421
Filed: Oct 5, 2021, 4:31 PM ET
Trade date: Oct 1-4, 2021
Filing delay: 4 days
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $1.25M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Gadicke AnsbertCIK 0001134655	10% Owner
MPM BioImpact LLCCIK 0001687078	10% Owner
UBS Oncology Impact Fund L.P.CIK 0001691428	10% Owner
Oncology Impact Fund (Cayman) Management L.P.CIK 0001721036	10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Oct 1, 2021	Common Stock	SSaleDisposed	−11,471	$27.00^F4	−$309,717	5,382,496	Indirect
Oct 4, 2021	Common Stock	SSaleDisposed	−34,659	$27.06^F7	−$937,872.54	5,347,837	Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)